Week in Review: Eluminex Raises $50 Million for Ophthalmology Drugs

Deals and Financings   Eluminex Biosciences of Suzhou closed a $50 million Series A Financing to develop novel therapies for unmet ophthalmology needs; Beijing Gene+, a company using next-gen sequencing for oncology diagnostics, raised $38 million in a Series B round; Shenzhen PreGene completed a $21 million B financing to develop fusion drug and nano-antibody drugs for oncology indications;   COVID-19 Pandemic   Sinopharm filed for China approval of a COVID-19 inactivated vaccine based on initial data from a global Phase III trial; Trials and Approvals   Bio-Thera Solutions of Guangzhou filed for European approval of its Avastin ® (bevacizumab) biosimilar in all Avastin indications; Suzhou Ascentage Pharma's novel Bcl-2 inhibitor was approved to start two China Phase Ib/II clinical trials in patients with multiple myeloma; Company News Changchun High & New Technology and Iceland 's Alvotech signed up Yangtze River Pharma to commercialize their eight biosimilar candidates; Genetron Health of Beijing will conduct a 150,000 person early screening test for liver cancer in Wuxi city using it blood-based HCCscreen TM . Stock Symbols: (SHA: 688177) (HK: 6855) (NSDQ: GTH) Share this with colleagues: // //